Nephros Inc.

NEPH Healthcare Medical Instruments & Supplies

Nephros Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 32.7% from fiscal 2024. In the quarter to June 2026, revenue grew 36.2%, EPS grew 450.0% and free cash flow fell 31.5%, each against the same quarter a year earlier.

3.65 0.14 +3.99%
Market cap
$38.1M
P/E
23.4×
Fwd P/E
76.0×
Dividend yield
—
F-score
7/9
Altman Z
−3.26
Beneish M
−2.60
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
22.91 45.29 46.12 36.38

+8 more quarters

P/S ratio
1.87 1.66 2.76 2.80
P/FCF ratio
0.00 0.00 34.07 19.35
P/Operating CF
56.92 (18.99) 225.16 507.02
P/B ratio
3.24 2.97 5.08 5.02
EV/Sales
1.64 1.45 2.47 2.51
EV/EBITDA
19.32 34.53 36.10 28.37
EV/FCF
(43.34) (58.62) 30.52 17.36
Current Ratio
4.07 4.55 4.06 4.34
Net Debt/EBITDA
(3.78) (32.40) (108.00) (14.86)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
4.36% 2.21% 2.17% 2.75%
Free Cash Flow Yield
(2.03%) (1.49%) 2.94% 5.17%
Free Cash Flow per Share
0.06 (0.16) 0.02 0.01
Book value per Share
1.10 1.00 0.96 0.94
Free Cash Flow
0.68 (1.67) 0.23 0.10
EV/EBIT
20.75 40.96 40.48 31.16
Other line items

Show all line items

Columns are period end dates